+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antidepressants Drugs Market by Drug Class, Product Type, Administration Route, Distribution Channel, Therapeutic Application - Global Forecast to 2030- Product Image
Antidepressants Drugs Market by Drug Class, Product Type, Administration Route, Distribution Channel, Therapeutic Application - Global Forecast to 2030- Product Image
Sale

Antidepressants Drugs Market by Drug Class, Product Type, Administration Route, Distribution Channel, Therapeutic Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715760
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antidepressants Drugs Market grew from USD 22.44 billion in 2024 to USD 24.80 billion in 2025. It is expected to continue growing at a CAGR of 10.12%, reaching USD 40.03 billion by 2030.

Unveiling the Dynamic World of Antidepressant Therapies

The global burden of mood disorders has propelled antidepressant therapies into the spotlight as indispensable tools in modern healthcare. Advances in neuroscience have deepened our understanding of neurotransmitter function, fueling innovation across multiple drug classes. At the same time, shifting patient expectations and digital health integrations are reshaping how therapies are prescribed, monitored, and refined. Against this backdrop, industry participants must navigate a landscape marked by patent expirations, intensifying generic competition, and the rising importance of tailored treatment pathways. This executive summary illuminates the critical forces driving growth and disruption, equipping stakeholders with the context needed to steer through emerging complexities and seize new opportunities.

Navigating Paradigm Shifts Shaping Antidepressant Care

In recent years, the antidepressant arena has witnessed paradigm-shifting developments that transcend incremental formulation tweaks. Personalized medicine initiatives are enabling clinicians to match patients with therapies based on genetic markers and real-world response patterns, while digital therapeutic adjuncts offer real-time symptom tracking and adherence support. Simultaneously, novel mechanisms targeting glutamatergic signaling and neuroinflammation are challenging the historical dominance of serotonin-centric approaches. Regulatory landscapes, too, are evolving to accommodate fast-track pathways for breakthrough therapies, accelerating time to market for drugs that address unmet clinical needs. Together, these forces are redefining treatment algorithms and setting the stage for a more dynamic, patient-centric era in mental health care.

Assessing the Ripple Effects of 2025 US Tariff Changes

The introduction of new tariff measures in the United States during 2025 is reverberating through global supply chains for active pharmaceutical ingredients and key excipients. Manufacturers reliant on overseas sourcing are re-evaluating procurement strategies, with some shifting toward regional production hubs to mitigate cost pressures and protect margins. These adjustments are translating into revised pricing strategies for both branded and generic therapies, prompting contract renegotiations with payers and group purchasing organizations. Even as stakeholders contend with short-term disruptions, there is an emerging consensus that diversified sourcing models and strategic inventory positioning will bolster resilience in the face of future policy shifts.

Decoding Market Segments to Drive Targeted Strategies

A nuanced understanding of market segmentation reveals distinct growth drivers and competitive intensities across therapy types, channels, and patient populations. Examining drug classes-from atypical antidepressants such as bupropion, mirtazapine, and trazodone to selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, monoamine oxidase inhibitors, and traditional tricyclic agents-uncovers shifting preferences tied to efficacy profiles and side-effect management. Within this context, branded formulations continue to capitalize on patented innovations while generic alternatives maintain cost-leadership, particularly in mature markets. Administration routes also diverge in performance: oral tablets remain the mainstay, yet parenteral injections and emerging transdermal systems are gaining traction among patients seeking faster onset or improved tolerability. Distribution is similarly variegated, with hospital pharmacies facilitating acute care needs even as online platforms reshape access for chronic therapy management, alongside the enduring role of retail outlets. Finally, therapeutic applications-from bipolar depression to seasonal affective disorder-highlight evolving clinical priorities. Conditions like generalized anxiety disorder, subdivided into panic disorder, post-traumatic stress, and social anxiety, as well as major depressive disorder with postpartum and treatment-resistant subgroups, demand tailored formulations and targeted patient support programs. This multilayered segmentation framework equips decision-makers with the insight to allocate R&D investments, refine market entries, and optimize product portfolios.

Unearthing Regional Trends That Define Global Demand

Regional dynamics continue to shape growth trajectories in nuanced ways. In the Americas, well-established reimbursement frameworks and high physician adoption rates for innovative therapies create a fertile environment for premium offerings, while generic penetration drives volume in cost-sensitive pockets. Across Europe, the Middle East, and Africa, the interplay of centralized procurement mechanisms and country-specific health technology assessments dictates market access strategies, with emerging markets in North Africa and the Gulf states representing untapped potential. Meanwhile, the Asia-Pacific region is characterized by rapid increases in depression diagnoses, expanding healthcare infrastructure, and a push toward local API manufacturing that lowers barriers to entry. Technology-enabled distribution models and patient assistance schemes are also rapidly evolving across these territories, offering fertile ground for both global pharmaceutical companies and nimble regional players.

Profiling Leading Innovators in the Antidepressant Arena

Leading pharmaceutical and biotech companies are executing bold strategies to secure competitive advantage. Major innovators are forging partnerships that pair novel mechanism research with agile development capabilities, resulting in faster transition from laboratory to clinic. Established generics manufacturers are leveraging economies of scale to capture share in both developed and emerging markets, while pursuing selective branded portfolio enhancements. Collaborations between pharmaceutical giants and digital health startups are also proliferating, aimed at integrating remote monitoring, adherence analytics, and patient engagement platforms into holistic care solutions. Across the spectrum, companies that excel in cross-functional alignment-merging R&D insights with market access acumen and digital engagement expertise-are emerging as frontrunners in the next phase of antidepressant innovation.

Actionable Strategies to Accelerate Market Leadership

To thrive in this dynamic environment, industry leaders must adopt a multipronged strategic approach. First, investing in personalized medicine platforms and companion diagnostics will enable precise targeting of patient subgroups and justify premium pricing. Second, building flexible manufacturing networks with diversified geographic footprints can mitigate tariff-driven cost volatility and ensure supply continuity. Third, deepening collaborations with payers and health systems through outcomes-based contracting will align incentives and accelerate access for high-value therapies. Fourth, embracing digital therapeutics and patient support ecosystems will drive adherence, improve outcomes, and differentiate offerings in a crowded marketplace. Finally, prioritizing real-world evidence generation and post-launch surveillance will strengthen product positioning and inform iterative development cycles. By executing these recommendations, organizations can convert emerging challenges into sustainable competitive advantages.

Rigorous Methodology Underpinning Comprehensive Analysis

Our analysis integrates both primary and secondary research methodologies to deliver robust insights. Secondary data were gathered from peer-reviewed journals, regulatory filings, clinical trial registries, and public financial disclosures, providing comprehensive coverage of historical trends and patent landscapes. Primary research consisted of in-depth interviews with key opinion leaders, clinicians, payers, and supply chain experts to validate assumptions and capture forward-looking perspectives. Quantitative data were triangulated using statistical models to identify correlations between pricing, access, and uptake across therapeutic classes and regions. Qualitative findings were synthesized through thematic coding to surface emerging themes in patient behavior and digital innovation. Throughout the process, peer reviews and validation checkpoints ensured the rigor and credibility of our conclusions.

Concluding Insights to Guide Stakeholder Decisions

As we conclude, it is clear that the antidepressant market stands at a pivotal juncture. The convergence of novel therapeutic mechanisms, digital health integration, and evolving policy dynamics necessitates agile strategies and informed decision-making. Segmentation insights illuminate where unmet needs persist and where competitive intensity demands differentiation. Regional nuances underscore the importance of tailored access and distribution models. And emerging and established players alike must balance near-term tariff challenges with long-term investment in R&D and patient engagement. By leveraging the evidence and recommendations presented here, stakeholders can confidently navigate complexity, mitigate risk, and capture opportunity in this rapidly transforming sector.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Atypical Antidepressant
      • Bupropion
      • Mirtazapine
      • Trazodone
    • Monoamine Oxidase Inhibitor
    • Selective Serotonin Reuptake Inhibitor
    • Serotonin Noradrenaline Reuptake Inhibitor
    • Tricyclic Antidepressant
  • Product Type
    • Branded
    • Generic
  • Administration Route
    • Oral
    • Parenteral
    • Transdermal
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Therapeutic Application
    • Bipolar Depression
    • Generalized Anxiety Disorder
      • Panic Disorder
      • Post Traumatic Stress Disorder
      • Social Anxiety Disorder
    • Major Depressive Disorder
      • Postpartum Depression
      • Treatment Resistant Depression
    • Obsessive Compulsive Disorder
    • Seasonal Affective Disorder
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Eli Lilly and Company
  • Pfizer Inc.
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antidepressants Drugs Market, by Drug Class
8.1. Introduction
8.2. Atypical Antidepressant
8.2.1. Bupropion
8.2.2. Mirtazapine
8.2.3. Trazodone
8.3. Monoamine Oxidase Inhibitor
8.4. Selective Serotonin Reuptake Inhibitor
8.5. Serotonin Noradrenaline Reuptake Inhibitor
8.6. Tricyclic Antidepressant
9. Antidepressants Drugs Market, by Product Type
9.1. Introduction
9.2. Branded
9.3. Generic
10. Antidepressants Drugs Market, by Administration Route
10.1. Introduction
10.2. Oral
10.3. Parenteral
10.4. Transdermal
11. Antidepressants Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Antidepressants Drugs Market, by Therapeutic Application
12.1. Introduction
12.2. Bipolar Depression
12.3. Generalized Anxiety Disorder
12.3.1. Panic Disorder
12.3.2. Post Traumatic Stress Disorder
12.3.3. Social Anxiety Disorder
12.4. Major Depressive Disorder
12.4.1. Postpartum Depression
12.4.2. Treatment Resistant Depression
12.5. Obsessive Compulsive Disorder
12.6. Seasonal Affective Disorder
13. Americas Antidepressants Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Antidepressants Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Antidepressants Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Eli Lilly and Company
16.3.2. Pfizer Inc.
16.3.3. AbbVie Inc.
16.3.4. GlaxoSmithKline plc
16.3.5. H. Lundbeck A/S
16.3.6. Otsuka Pharmaceutical Co., Ltd.
16.3.7. Johnson & Johnson
16.3.8. Teva Pharmaceutical Industries Ltd.
16.3.9. Sun Pharmaceutical Industries Ltd.
16.3.10. Cipla Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTIDEPRESSANTS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ANTIDEPRESSANTS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ANTIDEPRESSANTS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTIDEPRESSANTS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTIDEPRESSANTS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTIDEPRESSANTS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY BUPROPION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MIRTAZAPINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRAZODONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MONOAMINE OXIDASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEROTONIN NORADRENALINE REUPTAKE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY BIPOLAR DEPRESSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PANIC DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY POST TRAUMATIC STRESS DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SOCIAL ANXIETY DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY POSTPARTUM DEPRESSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEASONAL AFFECTIVE DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 60. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 61. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 62. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 65. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 66. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 68. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 107. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 109. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 110. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 111. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 114. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 115. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 117. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 118. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 119. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 122. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 131. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 133. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 135. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 138. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 139. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 141. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 143. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 146. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 171. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 173. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 175. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 178. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 187. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 189. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 190. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 191. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 194. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 195. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 196. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 197. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 199. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 202. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 219. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 220. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 221. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 222. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 223. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 226. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 227. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 229. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 230. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 231. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 234. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 243. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 244. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 245. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 246. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 247. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 250. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 251. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 252. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 253. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 254. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 255. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 257. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 258. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 276. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 277. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 278. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 279. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 280. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 282. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 283. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 284. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 285. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 286. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 287. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 288. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 290. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 291. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 292. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 293. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 294. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 295. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 296. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 298. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 299. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018

Companies Mentioned

The companies profiled in this Antidepressants Drugs market report include:
  • Eli Lilly and Company
  • Pfizer Inc.
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 24.8 Billion
Forecasted Market Value ( USD ) by 2030 $ 40.03 Billion
Compound Annual Growth Rate10.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antidepressant Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Antidepressant Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 140 Pages
  • Global
From
Antidepressants Market Report 2025 - Product Image

Antidepressants Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Antidepressant Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Antidepressant Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Antidepressants - Global Strategic Business Report - Product Image

Antidepressants - Global Strategic Business Report

  • Report
  • 174 Pages
  • Global
From
Antidepressants Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Product Type - Product Image

Antidepressants Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Product Type

  • Report
  • 86 Pages
  • Global
From

About the Antidepressant Market

The Antidepressant market is a subset of the Mental Disorders Drugs market, which includes medications used to treat mental health conditions such as depression, anxiety, bipolar disorder, and schizophrenia. Antidepressants are the most commonly prescribed medications for treating depression, and are typically divided into two categories: selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). These medications work by increasing the levels of serotonin and norepinephrine in the brain, which can help to improve mood and reduce symptoms of depression. Some of the major companies in the Antidepressant market include Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, and Bristol-Myers Squibb. These companies produce a variety of antidepressants, including SSRIs and SNRIs, as well as other medications used to treat mental health conditions. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.